These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
    Author: Crovari P, Crovari PC, Petrilli RC, Icardi GC, Bonanni P.
    Journal: Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356.
    Abstract:
    In a study comparing the safety and immunogenicity of a recombinant DNA yeast-derived hepatitis B vaccine with that of a plasma-derived vaccine in young female adults, 50 subjects were vaccinated with the former and 29 with the latter vaccine according to a 0, 1, and 6 month vaccination schedule. Results indicated that the yeast-derived vaccine was safe and highly immunogenic. Two months after the second vaccine dose, 86% of subjects seroconverted, a rate which increased to 100%, 30 days after the booster dose. Moreover, anti-HBs geometric mean titres increased progressively after the first two doses and rose markedly to 1098 IU/l after the booster dose. Although similar rates of seroconversion were obtained with both vaccines, the anti-HBs GMT of the plasma-derived vaccine was higher (P less than 0.05) than that elicited by the yeast-derived vaccine.
    [Abstract] [Full Text] [Related] [New Search]